文献速递神经免疫神经肌肉病

胸腺切除联合泼尼松治疗非胸腺瘤性重症肌无力的5年随访结果

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
PubMed 文献 · Lancet Neurol · 2019-01-25

MGTX随机试验的2年扩展研究显示,在非胸腺瘤性全身型重症肌无力患者中,胸腺切除联合泼尼松组在5年时的QMG评分和隔日泼尼松剂量均显著低于单用泼尼松组。两组不良事件发生率相近,无治疗相关死亡。

要点

  • 5年时胸腺切除组QMG评分显著低于单用泼尼松组。
  • 胸腺切除组隔日泼尼松剂量显著低于单用泼尼松组。
  • 两组不良事件发生率无显著差异,无治疗相关死亡。

核心结论

  • 在5年时,胸腺切除联合泼尼松较单用泼尼松持续改善非胸腺瘤性全身型重症肌无力患者的临床状态并减少泼尼松用量。

研究设计与样本

  • MGTX随机对照试验的2年扩展研究,在15个国家36个中心进行,纳入完成3年MGTX且愿意参与的患者,共68例进入扩展期。

主要发现

  • 至60个月时,单用泼尼松组33例中14例(42%)和胸腺切除联合泼尼松组35例中12例(34%)发生至少一次不良事件。
  • 扩展期未报告治疗相关死亡。

临床怎么用

  • 对于符合条件的非胸腺瘤性全身型重症肌无力患者,胸腺切除联合泼尼松可作为长期治疗选择以改善临床状态并减少激素用量。

局限性

  • 研究样本量较小,推广结论时需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone (MGTX) showed that thymectomy combined with prednisone was superior to prednisone alone in improving clinical status as measured by the Quantitative Myasthenia Gravis (QMG) score in patients with generalised non-thymomatous myasthenia gravis at 3 years. We investigated the long-term effects of thymectomy up to 5 years on clinical status, medication requirements, and adverse events. METHODS: We did a rater-blinded 2-year extension study at 36 centres in 15 countries for all patients who completed the randomised controlled MGTX and were willing to participate. MGTX patients were aged 18 to 65 years at enrolment, had generalised non-thymomatous myasthenia gravis of less than 5 years' duration, had acetylcholine receptor antibody titres of 1·00 nmol/L or higher (or concentrations of 0·50-0·99 nmol/L if diagnosis was confirmed by positive edrophonium or abnormal repetitive nerve stimulation, or abnormal single fibre electromyography), had Myasthenia Gravis Foundation of America Clinical Classification Class II-IV disease, and were on optimal anticholinesterase therapy with or without oral corticosteroids. In MGTX, patients were randomly assigned (1:1) to either thymectomy plus prednisone or prednisone alone. All patients in both groups received oral prednisone at doses titrated up to 100 mg on alternate days until they achieved minimal manifestation status. The primary endpoints of the extension phase were the time-weighted means of the QMG score and alternate-day prednisone dose from month 0 to month 60. Analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00294658. It is closed to new participants, with follow-up completed. FINDINGS: Of the 111 patients who completed the 3-year MGTX, 68 (61%) entered the extension study between Sept 1, 2009, and Aug 26, 2015 (33 in the prednisone alone group and 35 in the prednisone plus thymectomy group). 50 (74%) patients completed the 60-month assessment, 24 in the prednisone alone group and 26 in the prednisone plus thymectomy group. At 5 years, patients in the thymectomy plus prednisone group had significantly lower time-weighted mean QMG scores (5·47 [SD 3·87] vs 9·34 [5·08]; p=0·0007) and mean alternate-day prednisone doses (24 mg [SD 21] vs 48 mg [29]; p=0·0002) than did those in the prednisone alone group. 14 (42%) of 33 patients in the prednisone group, and 12 (34%) of 35 in the thymectomy plus prednisone group, had at least one adverse event by month 60. No treatment-related deaths were reported during the extension phase. INTERPRETATION: At 5 years, thymectomy plus prednisone continues to confer benefits in patients with generalised non-thymomatous myasthenia gravis compared with prednisone alone. Although caution is appropriate when generalising our findings because of the small sample size of our study, they nevertheless provide further support for the benefits of thymectomy in patients with generalised non-thymomatous myasthenia gravis. FUNDING: National Institutes of Health, National Institute of Neurological Disorders and Stroke.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Wolfe GI, Kaminski HJ, Aban IB, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019. PMID: 30692052. doi:10.1016/S1474-4422(18)30392-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。